▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / BNTX

BNTX — BioNTech SE

—
Nasdaq · Health Care · Biotechnology · CIK 1776985 ·
Last close
$86.50
Market Cap
$21.87B
52W High
$113.26
52W Low
$79.52
ADV30
931,020
Next earnings
2026-08-04
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 118,100,000 46,700,000 -677,500,000 -531,900,000 21,074,100,000 9,939,400,000 2,376,300,000
Dec 2025 907,400,000 574,100,000 -280,500,000 -305,000,000 21,988,600,000 7,675,400,000 2,764,400,000
Sep 2025 1,518,900,000 1,370,600,000 653,900,000 -28,700,000 21,341,100,000 10,092,900,000 2,863,800,000
Jun 2025 260,800,000 184,400,000 -478,500,000 -386,600,000 21,637,600,000 10,269,500,000 3,132,500,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$815,700,000
Investing CF
$-1,064,700,000
Financing CF
$-12,700,000
CapEx
$-209,800,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-5.07
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$17,430,000,000
Inventory
$103,800,000
Receivables
$612,200,000
ST Investments
$4,699,800,000
EBIT TTM
$-978,700,000
Pretax Income TTM
$-1,173,500,000
Interest Exp TTM
$14,600,000
Analysts
18

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,805,199,872
EBITDA
$-1,191,299,968
Free Cash Flow
$-428,112,512
Enterprise Value
$8,217,804,288
Total Cash
$13,706,600,448
Total Debt
$302,800,000
Shares Out
252,884,261
Trailing EPS
$-5.84
Book Value
$85.19
ROE
-6.7%
ROA
-4.2%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,869,900,000 -640,700,000 -1,136,100,000 21,988,600,000 2,764,400,000 — 456,000,000
Dec 2024 2,751,100,000 -709,400,000 -665,300,000 22,529,700,000 3,118,600,000 — 207,700,000
Dec 2023 3,819,000,000 875,600,000 930,300,000 23,006,300,000 2,760,400,000 — 5,371,400,000
Dec 2022 17,310,600,000 12,303,800,000 9,434,400,000 23,279,100,000 3,223,500,000 — 13,577,400,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.17

Max Pain — expiry 2026-06-18

max pain strike: $70.00 · spot: $86.50 · call oi: 986 · put oi: 69
Expected Move to 2026-06-18: ±$5.10 (5.90%) — implied range $81.40 – $91.60 · ATM straddle on $87.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MRNA Moderna, Inc. $18.94B $47.73 —
NBIX NEUROCRINE BIOSCIENCES INC $16.61B $165.24 —
BIIB BIOGEN INC. $29.39B $199.10 —
RVMD Revolution Medicines, Inc. $31.79B $149.55 —
EXEL EXELIXIS, INC. $13.32B $52.99 —

News headlines (Yahoo Finance, 1h cache)

BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study
2026-06-09 17:41 · Yahoo
Assessing BioNTech (BNTX) Valuation After Recent Share Price Weakness And Conflicting Growth Signals
2026-06-08 15:11 · Yahoo
Sector Update: Healthcare Stocks Higher Late Afternoon
2026-06-03 19:43 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
2026-06-01 15:11 · Yahoo
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
2026-05-30 18:15 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
2026-05-29 15:11 · Yahoo
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
2026-05-28 15:14 · Yahoo
BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says
2026-05-27 17:42 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
2026-05-27 15:08 · Yahoo
This Biotech Stock Is Stuck in the Red. Its Cancer Portfolio Is About to Change the Narrative.
2026-05-27 15:07 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →